Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Recent advances of anticancer nanomaterial vaccine platforms.

Created on 08 Jul 2026

Authors

Haixue Jia, Qiang Fu, Dianyu Wang, Ziyuan Wang, Xinming Zhao, Jianfeng Liu

Published in

Biomaterials science. Jul 08, 2026. Epub Jul 08, 2026.

Abstract

Although cancer vaccines have been proposed for decades, their clinical outcomes have remained largely unsatisfactory. Over the past decade, progress in deciphering the interaction between the immune system and cancer, along with widespread adoption of high-throughput sequencing technologies and improved MHC-peptide binding affinity prediction, have revitalized interest in cancer vaccine development. Nanomaterials benefit from the integration of tunable composition, modular architecture, and immunologically relevant dimensions, which collectively enable the rational design of immunomodulatory strategies tailored on demand, ensuring the reliable induction of antitumor immune responses. Given the spatiotemporal nature of immune responses, multifunctional nanomaterials can be further engineered to enable multivalent antigen presentation and controlled vaccine trafficking, thereby confining antitumor immune activation to desired contexts and minimizing off-target immune-related toxicities. Beyond conventional discussions of antigen delivery, this review emphasizes how rational nanomaterial design can be leveraged to regulate multiple stages of the cancer-immunity cycle, providing an updated perspective on the development of next-generation cancer vaccines. This Review will systematically summarize recent advances in nanomaterial-based cancer vaccines and discuss the key challenges and future directions in this rapidly evolving field.

PMID:
42418183
Bibliographic data and abstract were imported from PubMed on 08 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement